Details of the Drug

General Information of Drug (ID: DMEO794)

Drug Name
Galantamine
Synonyms
GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved [1], [2]
Therapeutic Class
Parasympathomimetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 287.35
Topological Polar Surface Area (xlogp) 1.8
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2.3 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 40.5 % [3]
Clearance
The renal clearance of drug is 65 mL/min [5]
Elimination
Renal clearance accounts for about 20C25% of total plasma clearance of the drug in healthy individuals: the elimination of galantamine has been shown to be decreased in subjects with renal impairment [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours [7]
Metabolism
The drug is metabolized via the CYP2D6 and CYP3A4 [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.44821 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.83% [9]
Vd
The volume of distribution (Vd) of drug is 175 L [7]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [4]
Chemical Identifiers
Formula
C17H21NO3
IUPAC Name
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
Canonical SMILES
CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
InChI
InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
InChIKey
ASUTZQLVASHGKV-JDFRZJQESA-N
Cross-matching ID
PubChem CID
9651
ChEBI ID
CHEBI:42944
CAS Number
357-70-0
DrugBank ID
DB00674
TTD ID
D0R9VR
INTEDE ID
DR0761
ACDINA ID
D00297

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Inhibitor [10], [11], [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Acetylcholinesterase (AChE) DTT ACHE 6.39E-02 -1.07 -1.15
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Galantamine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Donepezil DMIYG7Z Moderate Additive cholinergic effects by the combination of Galantamine and Donepezil. Alzheimer disease [8A20] [41]
Coadministration of a Drug Treating the Disease Different from Galantamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Additive cholinergic effects by the combination of Galantamine and Bethanechol. Abnormal micturition [MF50] [41]
Midostaurin DMI6E0R Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Midostaurin. Acute myeloid leukaemia [2A60] [42]
Idarubicin DMM0XGL Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Idarubicin. Acute myeloid leukaemia [2A60] [42]
Daunorubicin DMQUSBT Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Daunorubicin. Acute myeloid leukaemia [2A60] [42]
Oliceridine DM6MDCF Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Oliceridine. Acute pain [MG31] [42]
Scopolamine DMOM8AL Moderate Antagonize the effect of Galantamine when combined with Scopolamine. Addictive disorder [6C50-6C5Z] [43]
Mepyramine DMB4SFH Moderate Antagonize the effect of Galantamine when combined with Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [44]
Phenyltoloxamine DMKAEQW Moderate Antagonize the effect of Galantamine when combined with Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [44]
Tripelennamine DMZBU15 Moderate Antagonize the effect of Galantamine when combined with Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [43]
Metronidazole DMTIVEN Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Metronidazole. Amoebiasis [1A36] [42]
Bedaquiline DM3906J Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [42]
Cilostazol DMZMSCT Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Cilostazol. Arterial occlusive disease [BD40] [42]
Posaconazole DMUL5EW Moderate Decreased metabolism of Galantamine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [45]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Terbutaline. Asthma [CA23] [42]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Salbutamol. Asthma [CA23] [46]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Galantamine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [47]
Desipramine DMT2FDC Moderate Antagonize the effect of Galantamine when combined with Desipramine. Attention deficit hyperactivity disorder [6A05] [43]
Ofloxacin DM0VQN3 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Ofloxacin. Bacterial infection [1A00-1C4Z] [42]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Galantamine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [45]
Sparfloxacin DMB4HCT Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [42]
Gemifloxacin DMHT34O Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [42]
Norfloxacin DMIZ6W2 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Norfloxacin. Bacterial infection [1A00-1C4Z] [42]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Levofloxacin. Bacterial infection [1A00-1C4Z] [42]
Lomefloxacin DMVRH9C Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [42]
Retigabine DMGNYIH Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Retigabine. Behcet disease [4A62] [42]
Lomustine DMMWSUL Moderate Decreased metabolism of Galantamine caused by Lomustine mediated inhibition of CYP450 enzyme. Brain cancer [2A00] [45]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Eribulin. Breast cancer [2C60-2C6Y] [42]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Galantamine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Tucatinib DMBESUA Moderate Decreased metabolism of Galantamine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Tamoxifen DMLB0EZ Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Tamoxifen. Breast cancer [2C60-2C6Y] [42]
Bosutinib DMTI8YE Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Bosutinib. Breast cancer [2C60-2C6Y] [42]
PF-04449913 DMSB068 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [42]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [42]
Halothane DM80OZ5 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Halothane. Corneal disease [9A76-9A78] [42]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Galantamine and Propofol. Corneal disease [9A76-9A78] [49]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Sevoflurane. Corneal disease [9A76-9A78] [42]
Probucol DMVZQ2M Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Probucol. Coronary atherosclerosis [BA80] [42]
Clofazimine DMEBOFW Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Clofazimine. Crohn disease [DD70] [42]
Mifepristone DMGZQEF Moderate Decreased metabolism of Galantamine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [46]
Pasireotide DMHM7JS Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Pasireotide. Cushing syndrome [5A70] [42]
Sertraline DM0FB1J Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Sertraline. Depression [6A70-6A7Z] [42]
Trimipramine DM1SC8M Moderate Antagonize the effect of Galantamine when combined with Trimipramine. Depression [6A70-6A7Z] [43]
Cyclobenzaprine DM1YBRM Moderate Antagonize the effect of Galantamine when combined with Cyclobenzaprine. Depression [6A70-6A7Z] [43]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Galantamine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [45]
Paroxetine DM5PVQE Moderate Decreased metabolism of Galantamine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [45]
Escitalopram DMFK9HG Moderate Decreased metabolism of Galantamine caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [45]
OPC-34712 DMHG57U Moderate Antagonize the effect of Galantamine when combined with OPC-34712. Depression [6A70-6A7Z] [43]
Clomipramine DMINRKW Moderate Antagonize the effect of Galantamine when combined with Clomipramine. Depression [6A70-6A7Z] [43]
Doxepin DMPI98T Moderate Antagonize the effect of Galantamine when combined with Doxepin. Depression [6A70-6A7Z] [44]
Maprotiline DMPWB7T Moderate Antagonize the effect of Galantamine when combined with Maprotiline. Depression [6A70-6A7Z] [43]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Galantamine when combined with Mepenzolate. Digestive system disease [DE2Z] [43]
Oxybutynine DMJPBAX Moderate Antagonize the effect of Galantamine when combined with Oxybutynine. Discovery agent [N.A.] [43]
Tetrabenazine DMYWQ0O Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [42]
Meclizine DMS7T13 Moderate Antagonize the effect of Galantamine when combined with Meclizine. Dizziness and giddiness [MB48] [43]
Deutetrabenazine DMUPFLI Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Deutetrabenazine. Dystonic disorder [8A02] [42]
Ingrezza DMVPLNC Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Ingrezza. Dystonic disorder [8A02] [42]
Rufinamide DMWE60C Moderate Increased metabolism of Galantamine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Galantamine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [43]
Tropicamide DM1D90W Moderate Antagonize the effect of Galantamine when combined with Tropicamide. Eye anterior segment structural developmental anomaly [LA11] [50]
Solifenacin DMG592Q Moderate Antagonize the effect of Galantamine when combined with Solifenacin. Functional bladder disorder [GC50] [43]
Mirabegron DMS1GYT Moderate Decreased metabolism of Galantamine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [51]
Tolterodine DMSHPW8 Moderate Antagonize the effect of Galantamine when combined with Tolterodine. Functional bladder disorder [GC50] [43]
Itraconazole DMCR1MV Moderate Decreased metabolism of Galantamine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Pentamidine DMHZJCG Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Pentamidine. Fungal infection [1F29-1F2F] [42]
Terbinafine DMI6HUW Moderate Decreased metabolism of Galantamine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [52]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Galantamine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Propantheline DM2EN6G Moderate Antagonize the effect of Galantamine when combined with Propantheline. Gastric ulcer [DA60] [43]
Sunitinib DMCBJSR Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [42]
Cyclopentolate DMA8LM5 Moderate Antagonize the effect of Galantamine when combined with Cyclopentolate. General examination [QA00] [50]
Boceprevir DMBSHMF Moderate Decreased metabolism of Galantamine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [45]
Telaprevir DMMRV29 Moderate Decreased metabolism of Galantamine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [45]
Rifapentine DMCHV4I Moderate Increased metabolism of Galantamine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [53]
Delavirdine DM3NF5G Moderate Decreased metabolism of Galantamine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Galantamine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Fostemsavir DM50ILT Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [42]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Galantamine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [42]
Darunavir DMN3GCH Moderate Decreased metabolism of Galantamine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Conivaptan DM1V329 Moderate Decreased metabolism of Galantamine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [45]
Belladonna DM2RBWK Moderate Antagonize the effect of Galantamine when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [43]
Propiomazine DMKY8V1 Moderate Antagonize the effect of Galantamine when combined with Propiomazine. Insomnia [7A00-7A0Z] [43]
ITI-007 DMUQ1DO Moderate Antagonize the effect of Galantamine when combined with ITI-007. Insomnia [7A00-7A0Z] [43]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Galantamine and Polyethylene glycol. Irritable bowel syndrome [DD91] [55]
Clidinium DMUMQZ0 Moderate Antagonize the effect of Galantamine when combined with Clidinium. Irritable bowel syndrome [DD91] [43]
Physostigmine DM2N0TO Moderate Additive cholinergic effects by the combination of Galantamine and Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [41]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Galantamine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [47]
PF-06463922 DMKM7EW Moderate Increased metabolism of Galantamine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [56]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Galantamine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [57]
Osimertinib DMRJLAT Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Osimertinib. Lung cancer [2C25] [42]
Selpercatinib DMZR15V Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Selpercatinib. Lung cancer [2C25] [42]
Lumefantrine DM29GAD Moderate Decreased metabolism of Galantamine caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [46]
Halofantrine DMOMK1V Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Halofantrine. Malaria [1F40-1F45] [42]
Hydroxychloroquine DMSIVND Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Hydroxychloroquine. Malaria [1F40-1F45] [42]
Primaquine DMWQ16I Moderate Decreased metabolism of Galantamine caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [45]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [42]
Idelalisib DM602WT Moderate Decreased metabolism of Galantamine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [45]
Arsenic trioxide DM61TA4 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [42]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Galantamine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [58]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Galantamine and LGX818. Melanoma [2C30] [59]
Exjade DMHPRWG Moderate Decreased metabolism of Galantamine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [60]
Panobinostat DM58WKG Moderate Decreased metabolism of Galantamine caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [61]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Thalidomide. Multiple myeloma [2A83] [46]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Galantamine and Siponimod. Multiple sclerosis [8A40] [46]
Fingolimod DM5JVAN Moderate Increased risk of atrioventricular block by the combination of Galantamine and Fingolimod. Multiple sclerosis [8A40] [62]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Galantamine and Ozanimod. Multiple sclerosis [8A40] [63]
Neostigmine DM6T2J3 Moderate Additive cholinergic effects by the combination of Galantamine and Neostigmine. Myasthenia gravis [8C6Y] [41]
Edrophonium DMCRQHB Moderate Additive cholinergic effects by the combination of Galantamine and Edrophonium. Myasthenia gravis [8C6Y] [41]
Ambenonium DMOP0BL Moderate Additive cholinergic effects by the combination of Galantamine and Ambenonium. Myasthenia gravis [8C6Y] [41]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Romidepsin. Mycosis fungoides [2B01] [42]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Galantamine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Nilotinib DM7HXWT Moderate Decreased metabolism of Galantamine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [64]
Dasatinib DMJV2EK Moderate Decreased metabolism of Galantamine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [65]
Phenindamine DMDTC7R Moderate Antagonize the effect of Galantamine when combined with Phenindamine. Nasopharyngitis [CA00] [43]
Promethazine DM6I5GR Moderate Antagonize the effect of Galantamine when combined with Promethazine. Nausea/vomiting [MD90] [43]
Rolapitant DM8XP26 Moderate Decreased metabolism of Galantamine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [66]
Cyclizine DM9G7BS Moderate Antagonize the effect of Galantamine when combined with Cyclizine. Nausea/vomiting [MD90] [43]
Granisetron DMIUW25 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Granisetron. Nausea/vomiting [MD90] [42]
Dolasetron DMMG26Z Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Dolasetron. Nausea/vomiting [MD90] [42]
Ondansetron DMOTQ1I Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Ondansetron. Nausea/vomiting [MD90] [42]
Bupropion DM5PCS7 Major Decreased metabolism of Galantamine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [42]
Entrectinib DMMPTLH Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Entrectinib. Non-small cell lung cancer [2C25] [42]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Galantamine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [67]
Levomethadyl Acetate DM06HG5 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Levomethadyl Acetate. Opioid use disorder [6C43] [46]
Lofexidine DM1WXA6 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Lofexidine. Opioid use disorder [6C43] [42]
Rucaparib DM9PVX8 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Rucaparib. Ovarian cancer [2C73] [42]
Flavoxate DMKV4NL Moderate Antagonize the effect of Galantamine when combined with Flavoxate. Pain [MG30-MG3Z] [43]
Buprenorphine DMPRI8G Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Buprenorphine. Pain [MG30-MG3Z] [42]
Triclabendazole DMPWGBR Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Triclabendazole. Parasitic worm infestation [1F90] [42]
Biperiden DME78OA Moderate Antagonize the effect of Galantamine when combined with Biperiden. Parkinsonism [8A00] [43]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Pimavanserin. Parkinsonism [8A00] [42]
Orphenadrine DMW542E Moderate Antagonize the effect of Galantamine when combined with Orphenadrine. Parkinsonism [8A00] [43]
Apomorphine DMX38HQ Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Apomorphine. Parkinsonism [8A00] [42]
Ranitidine DM0GUSX Moderate Antagonize the effect of Galantamine when combined with Ranitidine. Peptic ulcer [DA61] [43]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of Galantamine when combined with Methylscopolamine. Peptic ulcer [DA61] [43]
Famotidine DMRL3AB Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Famotidine. Peptic ulcer [DA61] [42]
Macimorelin DMQYJIR Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Macimorelin. Pituitary gland disorder [5A60-5A61] [42]
Lefamulin DME6G97 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Lefamulin. Pneumonia [CA40] [42]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Galantamine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [45]
Degarelix DM3O8QY Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Degarelix. Prostate cancer [2C82] [42]
Relugolix DMK7IWL Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Relugolix. Prostate cancer [2C82] [42]
Levomepromazine DMIKFEL Moderate Antagonize the effect of Galantamine when combined with Levomepromazine. Psychotic disorder [6A20-6A25] [43]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Galantamine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [68]
Gatifloxacin DMSL679 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [42]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Galantamine caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [45]
Mesoridazine DM2ZGAN Moderate Antagonize the effect of Galantamine when combined with Mesoridazine. Schizophrenia [6A20] [43]
Aripiprazole DM3NUMH Moderate Antagonize the effect of Galantamine when combined with Aripiprazole. Schizophrenia [6A20] [43]
Iloperidone DM6AUFY Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Iloperidone. Schizophrenia [6A20] [42]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Paliperidone. Schizophrenia [6A20] [42]
Perphenazine DMA4MRX Moderate Antagonize the effect of Galantamine when combined with Perphenazine. Schizophrenia [6A20] [43]
Molindone DMAH70G Moderate Antagonize the effect of Galantamine when combined with Molindone. Schizophrenia [6A20] [43]
Thiothixene DMDINC4 Moderate Antagonize the effect of Galantamine when combined with Thiothixene. Schizophrenia [6A20] [43]
Trifluoperazine DMKBYWI Moderate Antagonize the effect of Galantamine when combined with Trifluoperazine. Schizophrenia [6A20] [43]
Risperidone DMN6DXL Moderate Antagonize the effect of Galantamine when combined with Risperidone. Schizophrenia [6A20] [43]
Asenapine DMSQZE2 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Asenapine. Schizophrenia [6A20] [42]
Pimozide DMW83TP Moderate Antagonize the effect of Galantamine when combined with Pimozide. Schizophrenia [6A20] [43]
Vardenafil DMTBGW8 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Vardenafil. Sexual dysfunction [HA00-HA01] [42]
Vandetanib DMRICNP Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [42]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [42]
Doxorubicin DMVP5YE Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [42]
Pitolisant DM8RFNJ Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Pitolisant. Somnolence [MG42] [42]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [42]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Galantamine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [69]
Lenvatinib DMB1IU4 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Lenvatinib. Thyroid cancer [2D10] [42]
Cabozantinib DMIYDT4 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Cabozantinib. Thyroid cancer [2D10] [42]
Tizanidine DMR2IQ4 Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Tizanidine. Tonus and reflex abnormality [MB47] [42]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Galantamine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [68]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Galantamine and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [68]
Methdilazine DMAUHQX Moderate Antagonize the effect of Galantamine when combined with Methdilazine. Vasomotor/allergic rhinitis [CA08] [43]
Carbinoxamine DMCT31R Moderate Antagonize the effect of Galantamine when combined with Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [43]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Galantamine when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [44]
Brompheniramine DMFOVSD Moderate Antagonize the effect of Galantamine when combined with Brompheniramine. Vasomotor/allergic rhinitis [CA08] [43]
Acrivastine DMTIGA0 Moderate Antagonize the effect of Galantamine when combined with Acrivastine. Vasomotor/allergic rhinitis [CA08] [43]
Azatadine DMZ80SB Moderate Antagonize the effect of Galantamine when combined with Azatadine. Vasomotor/allergic rhinitis [CA08] [43]
Procainamide DMNMXR8 Moderate Antagonize the effect of Galantamine when combined with Procainamide. Ventricular tachyarrhythmia [BC71] [43]
Propafenone DMPIBJK Moderate Decreased metabolism of Galantamine caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [45]
Flecainide DMSQDLE Moderate Increased risk of ventricular arrhythmias by the combination of Galantamine and Flecainide. Ventricular tachyarrhythmia [BC71] [42]
⏷ Show the Full List of 176 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone E00626 Not Available Disintegrant
Dibutyl sebacate E00160 7986 Plasticizing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Galantamine 16 mg capsule 16 mg 24 HR Extended Release Oral Capsule Oral
Galantamine 24 mg capsule 24 mg 24 HR Extended Release Oral Capsule Oral
Galantamine 8 mg capsule 8 mg 24 HR Extended Release Oral Capsule Oral
Galantamine 12 mg tablet 12 mg Oral Tablet Oral
Galantamine 4 mg tablet 4 mg Oral Tablet Oral
Galantamine 8 mg tablet 8 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6693).
2 Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
3 Mictoryl monograph
4 BDDCS applied to over 900 drugs
5 Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.
6 Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76.
7 FDA Approved Drug Products: RAZADYNE (galantamine hydrobromide), for oral use
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
11 Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. Neuroreport. 2009 Feb 18;20(3):285-8.
12 Acetylcholinesterase inhibitors enhance cognitive functions in rats following hypobaric hypoxia. Behav Brain Res. 2009 Oct 12;203(1):1-14.
13 Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
24 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
25 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
26 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
27 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
28 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
29 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
30 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
31 Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
33 Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
34 Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
35 Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
36 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
37 Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
38 The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
39 Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
40 Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.
41 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
42 Canadian Pharmacists Association.
43 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
44 Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7. [PMID: 15571547]
45 Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
46 Cerner Multum, Inc. "Australian Product Information.".
47 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
48 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
49 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
50 Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659]
51 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
52 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
53 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
54 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
55 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
56 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
59 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
60 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
61 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
62 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
64 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
66 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
67 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
68 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
69 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.